Last reviewed · How we verify
cDMARD
cDMARDs work by inhibiting the enzyme peptidyl arginine deiminase, which is involved in the production of autoantibodies.
cDMARDs work by inhibiting the enzyme peptidyl arginine deiminase, which is involved in the production of autoantibodies. Used for Rheumatoid arthritis, Psoriatic arthritis, Juvenile idiopathic arthritis.
At a glance
| Generic name | cDMARD |
|---|---|
| Sponsor | Eli Lilly and Company |
| Drug class | cDMARD |
| Target | peptidyl arginine deiminase |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This inhibition leads to a decrease in the production of autoantibodies, which are thought to contribute to the development of autoimmune diseases. By reducing the levels of these autoantibodies, cDMARDs can help to slow down disease progression and reduce symptoms. However, the exact mechanisms by which cDMARDs exert their therapeutic effects are not fully understood.
Approved indications
- Rheumatoid arthritis
- Psoriatic arthritis
- Juvenile idiopathic arthritis
Common side effects
- Increased risk of infections
- Liver enzyme elevations
- Neutropenia
Key clinical trials
- Coronavirus Anxiety in Patients Using Biologic vs Conventional DMARDs
- Ultrasound to Guide Treatment Decisions in Patients With Rheumatoid Arthritis According to a T2T Approach (NA)
- Study of Salvage Therapy to Treat Patients with Granulomatosis with Polyangiitis (PHASE3)
- IL-6, IL-12, IL-15 and IL-23 Expression Levels in Rheumatoid Arthritis Patients
- An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis (PHASE3)
- Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Therapy of Conventional Disease-modifying Antirheumatic Drugs (cDMARDs) to cDMARD Plus ANti-TNF Versus cDMARDs in Real World
- A Moderate to Severe Rheumatoid Arthritis Study (PHASE3)
- A Study in Moderate to Severe Rheumatoid Arthritis Participants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cDMARD CI brief — competitive landscape report
- cDMARD updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI